



End Of Warranty Inspections and Results

Judah Moseson PE CEM
Director of Technical Services
June 2012

Introduction to Infigen Energy

infigen

- Infigen Energy ("Infigen") is a leading independent renewable energy business with interests in 24 wind farms (1,646 MW installed capacity) across the United States and Australia.
- The name Infigen is derived from the words *infinite* and *generation*
 - infinite, reflecting the unlimited availability of renewable fuel sources
 - generation, relating to a core function of our business
- Founded in June 2003 and listed on the Australian Securities Exchange (ASX) in October 2005.
- A leading US renewable energy business
 - Large operational wind energy business (1,089MW) with 18 operating projects in 9 states
 - Actively developing utility scale wind and solar projects
 - Headquartered in Dallas, Texas – 150 US employees
 - >75% of capacity post warranty – most with in-house operations & maintenance
- Australia's leading specialist renewable energy business
 - Leading operational wind energy business (556MW)
 - Diversified, high quality wind energy development pipeline

US

Total Capacity*: 1,089.4MW
Capacity Factor: 37%

Allegheny Ridge 1	GSG
Aragonne	Jersey Atlantic
Bear Creek	Kumeyaay
Blue Canyon	Meridota
Buena Vista	Sweetwater 1
Caprock	Sweetwater 2
Cedar Creek	Sweetwater 3
Combine Hills	Sweetwater 4
Crescent Ridge	Sweetwater 5

* Represents Infigen's % ownership of Class B Member Units.




AUSTRALIA

Total Capacity: 508.3MW
Capacity Factor: 36%

Alinta
Capital
Lake Bonney 1
Lake Bonney 2
Lake Bonney 3



The Importance of Getting it Right



The Warranty is to Protect Against Design Defects

- OEM's Goals are to protect their brand and minimise costs
- Owner must manage the oversight of work done to be sure equipment is ready to make life cycle.

The Cost to Operate is on the Owner Post Warranty

- 75% of the Project Life still to run Post Warranty!
- Having Design Defects Identified and Resolved prior to EOW is Critical
- **Proper EOW Inspection can determine who's responsible for possible thousands, if not millions, in repair costs in near and long term.**

Beginning the Process

- Start early enough to enable you to process your claim prior to the first unit on the project exiting its warranty.
- Identify your Inspection Contractor
- Identify the Experts you may need to substantiate any claims
- Notify the OEM and keep them abreast of your schedule

Qualifying Your Contractor

- **Start With Safety!** Make sure your vendor has a qualified safety program and historically good results.
- Make sure they have specific experience on your turbine make and model.
- Performing inspections is a core part of their established business.
- Always get references!

The Scope of The Inspection

Always Include:

- Bore Scope Every Gearbox
- Telescope Every Blade
- Pitch and Yaw Systems
- Cables, Ladders, Bolts and even Paint
- Converters and Cooling Systems
- Oil Samples

Remember to:

- Go Through Nacelle in Detail
- Look for fluid leaks/Proper lubrication
- Listen for unusual noises during operation


RESULTS OF ACTUAL INSPECTIONS



RESULTS OF ACTUAL INSPECTIONS



RESULTS OF ACTUAL INSPECTIONS



RESULTS OF ACTUAL INSPECTIONS



RESULTS OF ACTUAL INSPECTIONS



Key Points

- Make Claims during the Warranty Period
- Identify any Serial Defects
- Hire Industry Gearbox and Blade Experts to substantiate your claims to OEM's
- Read your Contracts carefully, seek legal advice for understanding your rights
- Be Assertive! But BE FAIR!!
- The results can vary widely depending on OEM/Local Leadership. Your results will help to understand whether to engage the OEM in Post Warranty Operations or not.

EOW INSPECTIONS

infigen

QUESTIONS?



infigen

Disclaimer



This publication is issued by Infigen Energy Limited ("IEL"), Infigen Energy (Bermuda) Limited ("IEBL") and Infigen Energy Trust ("IET"), with Infigen Energy RE Limited ("IERL") as responsible entity of IET (collectively "Infigen"). Infigen and its related entities, directors, officers and employees (collectively "Infigen Entities") do not accept, and expressly disclaim, any liability whatsoever (including for negligence) for any loss howsoever arising from any use of this publication or its contents. This publication is not intended to constitute legal, tax or accounting advice or opinion. No representation or warranty, expressed or implied, is made as to the accuracy, completeness or thoroughness of the content of the information. The recipient should consult with its own legal, tax or accounting advisers as to the accuracy and application of the information contained herein and should conduct its own due diligence and other enquiries in relation to such information.

The information in this presentation has not been independently verified by the Infigen Entities. The Infigen Entities disclaim any responsibility for any errors or omissions in such information, including the financial calculations, projections and forecasts. No representation or warranty is made by or on behalf of the Infigen Entities that any projection, forecast, calculation, forward-looking statement, assumption or estimate contained in this presentation should or will be achieved. None of the Infigen Entities guarantee the performance of Infigen, the repayment of capital or a particular rate of return on Infigen Stapled Securities.

IEL and IEBL are not licensed to provide financial product advice. This publication is for general information only and does not constitute financial product advice, including personal financial product advice, or an offer, invitation or recommendation in respect of securities, by IEL, IEBL or any other Infigen Entities. Please note that, in providing this presentation, the Infigen Entities have not considered the objectives, financial position or needs of the recipient. The recipient should obtain and rely on its own professional advice from its tax, legal, accounting and other professional advisers in respect of the recipient's objectives, financial position or needs.

This presentation does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of the Infigen Entities.

IMPORTANT NOTICE

Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy Infigen securities in the United States or any other jurisdiction.

Securities may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S under the US Securities Act of 1933) unless they are registered under the Securities Act or exempt from registration.